摘要
为观察早期应用DF－521对脑梗塞近期疗效的影响，设DF－521治疗组及常规治疗组各30例．前者除常规治疗外，在早期应用了DF－521治疗．出院时治愈率分别为53．3％及26．7％，显效治愈率分别为93．3％及60％．两组平均住院天数分别为19．3±7．6及25．1±6．2天．结果提示早期应用DF．521能明显提高脑梗塞的疗效，改善病残程度，还能明显缩短住院天数．因此，早期应用DF－521结合其它常规措施综合治疗，不失为脑梗塞的一种较好治疗万法．
To observe the effects of DF-521(batroxobin) on acute-stage cerebral infarction, we divided the patients into DF-521 treating group(n=30) and routine treating group(n=30). In DF-521 group,patients were treated with batroxobin intravenously in the early stage of attacks of cerebral infarction. Both groups received the routine methods of treatment. It was showed that the curative rate was 53.3% and 26.7%(P<0.05), and the efficacious rate was 93.3% and 60%(P<0.01) respectively in DF-521 and control groups. It was also showed that the mean in-hospital time was 19.3 ± 7. 6 days and 25.1 ± 6.2 days respectively in DF-521 and control groups(P<0.01). It is suggested that the early application of batroxobin in patients with acute-stage cerebral infarction can remarkably increase curative effects, decrease inhospital days. Therefore, it may be a better method for the treatment of cerebral infarction using batroxobin in the early stage of attaks in combination with routine treatment.
出处
《伤残医学杂志》
1997年第1期29-30,共2页
Medical Journal of Trauma and Disability
关键词
DF-521
脑梗塞
疗效
DF-521 (tobishi batroxobin) Cerebral infarction Curative effect
